Multivariate meta-analysis of controlled drug studies for obsessive-compulsive disorder - PubMed (original) (raw)
Meta-Analysis
Multivariate meta-analysis of controlled drug studies for obsessive-compulsive disorder
Deborah L Ackerman et al. J Clin Psychopharmacol. 2002 Jun.
Abstract
Meta-analytic reviews of placebo-controlled studies for obsessive-compulsive disorder have found that clomipramine is more effective than drugs with more selective actions on serotonin reuptake, whereas in most direct comparisons, clomipramine's superiority has been less obvious. The authors used metaregression to identify sources of he-terogeneity in placebo-controlled trials of clomipramine, fluvoxamine, sertraline, and paroxetine. They evaluated such patient characteristics as age, gender, age of obsessive-compulsive disorder (OCD) onset, and baseline severity of OCD and depression, and such study characteristics as exclusion or inclusion criteria, length of single-blind prerandomization period, length of trial, number of subjects, and publication year. We found considerable heterogeneity across studies that was associated, in part, with publication year, length of single-blind prerandomization period, length of trial, and severity of patients' OCD. The apparent superiority of clomipramine persisted after controlling for these factors. The authors also confirmed previous reports that placebo response is higher in more recent studies. Meta-analyses can help characterize responders and nonresponders. The authors urge investigators to provide summaries of patient characteristics, especially baseline severity, age at onset, and duration of OCD, by patients' response.
Comment in
- Review: in obsessive-compulsive disorder, clomipramine may be more effective than selective serotonin reuptake inhibitors after controlling for other factors.
Hollander E, Kahn J. Hollander E, et al. Evid Based Ment Health. 2003 Feb;6(1):23. doi: 10.1136/ebmh.6.1.23. Evid Based Ment Health. 2003. PMID: 12588829 No abstract available. - A case of obsessive-compulsive disorder successfully treated with agomelatine monotherapy.
De Berardis D, Serroni N, Campanella D, Olivieri L, Moschetta FS, Conti CM, Conti P, Di Giannantonio M. De Berardis D, et al. J Clin Psychopharmacol. 2012 Apr;32(2):289-90. doi: 10.1097/JCP.0b013e318249298c. J Clin Psychopharmacol. 2012. PMID: 22388158 No abstract available.
Similar articles
- A review of the efficacy of selective serotonin reuptake inhibitors in obsessive-compulsive disorder.
Pigott TA, Seay SM. Pigott TA, et al. J Clin Psychiatry. 1999 Feb;60(2):101-6. doi: 10.4088/jcp.v60n0206. J Clin Psychiatry. 1999. PMID: 10084636 Review. - Use of factor-analyzed symptom dimensions to predict outcome with serotonin reuptake inhibitors and placebo in the treatment of obsessive-compulsive disorder.
Mataix-Cols D, Rauch SL, Manzo PA, Jenike MA, Baer L. Mataix-Cols D, et al. Am J Psychiatry. 1999 Sep;156(9):1409-16. doi: 10.1176/ajp.156.9.1409. Am J Psychiatry. 1999. PMID: 10484953 - Serotonin-norepinephrine reuptake inhibitors in the treatment of obsessive-compulsive disorder: A critical review.
Dell'Osso B, Nestadt G, Allen A, Hollander E. Dell'Osso B, et al. J Clin Psychiatry. 2006 Apr;67(4):600-10. doi: 10.4088/jcp.v67n0411. J Clin Psychiatry. 2006. PMID: 16669725 Review. - Efficacy of drug treatment in obsessive-compulsive disorder. A meta-analytic review.
Piccinelli M, Pini S, Bellantuono C, Wilkinson G. Piccinelli M, et al. Br J Psychiatry. 1995 Apr;166(4):424-43. doi: 10.1192/bjp.166.4.424. Br J Psychiatry. 1995. PMID: 7795913 Clinical Trial. - Sustained response versus relapse: the pharmacotherapeutic goal for obsessive-compulsive disorder.
Fineberg NA, Pampaloni I, Pallanti S, Ipser J, Stein DJ. Fineberg NA, et al. Int Clin Psychopharmacol. 2007 Nov;22(6):313-22. doi: 10.1097/YIC.0b013e32825ea312. Int Clin Psychopharmacol. 2007. PMID: 17917549 Review.
Cited by
- Initial severity and antidepressant efficacy for anxiety disorders, obsessive-compulsive disorder, and posttraumatic stress disorder: An individual patient data meta-analysis.
de Vries YA, Roest AM, Burgerhof JGM, de Jonge P. de Vries YA, et al. Depress Anxiety. 2018 Jun;35(6):515-522. doi: 10.1002/da.22737. Epub 2018 Apr 16. Depress Anxiety. 2018. PMID: 29659102 Free PMC article. - Managing obsessive compulsive disorder.
Brakoulias V. Brakoulias V. Aust Prescr. 2015 Aug;38(4):121-3. doi: 10.18773/austprescr.2015.040. Epub 2015 Aug 3. Aust Prescr. 2015. PMID: 26648639 Free PMC article. Review. - Still Struggling: characteristics of youth with OCD who are partial responders to medication treatment.
Freeman J, Sapyta J, Garcia A, Fitzgerald D, Khanna M, Choate-Summers M, Moore P, Chrisman A, Haff N, Naeem A, March J, Franklin M. Freeman J, et al. Child Psychiatry Hum Dev. 2011 Aug;42(4):424-41. doi: 10.1007/s10578-011-0227-4. Child Psychiatry Hum Dev. 2011. PMID: 21484416 Free PMC article. Clinical Trial. - Pharmacological treatment of obsessive-compulsive disorder.
Pittenger C, Bloch MH. Pittenger C, et al. Psychiatr Clin North Am. 2014 Sep;37(3):375-91. doi: 10.1016/j.psc.2014.05.006. Epub 2014 Jul 24. Psychiatr Clin North Am. 2014. PMID: 25150568 Free PMC article. Review. - Monoamine transporters: vulnerable and vital doorkeepers.
Lin Z, Canales JJ, Björgvinsson T, Thomsen M, Qu H, Liu QR, Torres GE, Caine SB. Lin Z, et al. Prog Mol Biol Transl Sci. 2011;98:1-46. doi: 10.1016/B978-0-12-385506-0.00001-6. Prog Mol Biol Transl Sci. 2011. PMID: 21199769 Free PMC article. Review.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical